Mood Disorders News

Recent findings indicated a polygenic risk gradient across schizophrenia and bipolar disorder, which was associated with the presence and severity of mood-incongruent psychotic symptoms.

Most individuals seeking outpatient mental health care reported their mood and anxiety levels were linked to physical activity.

Following implementation of the peer review prior authorization policy, atypical antipsychotic use significantly decreased among children aged younger than 5 to 8 years in Medicaid programs.

Full long-term findings, indicating efficacy and safety of Ingrezza for tardive dyskinesia, were recently published in Journal of Clinical Psychiatry, according to Neurocrine Biosciences Inc.

The FDA recently approved Abilify MyCite, aripiprazole tablets with an ingestible sensor from Otsuka Pharmaceuticals and Proteus Digital Health, to digitally track if patients have ingested medication for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and adjunctive treatment for depression.

Sage Therapeutics recently announced phase 3 findings that indicated efficacy and safety of brexanolone, formerly known as SAGE-547, for postpartum depression.

Women with a history of anxiety or mood disorder in the 2 years before pregnancy had a moderately increased risk for developing gestational diabetes vs. women who did not have an anxiety or mood disorder, according to an analysis of population-level data in Canada.

Providing access to an internet support group did not provide additional benefit to computerized cognitive behavioral therapy; however, computerized therapy alone was more effective than usual care for mood and anxiety disorders.

Lower baseline symptom severity was associated with greater treatment response to olanzapine among patients with bipolar I disorder.

Findings presented at the Anesthesiology Annual Meeting indicated positive associations between postpartum depression and BMI, gestational age, and delivery season.